(New York Times) Apr 19, 2018 - The promise of new treatments like immunotherapies have blurred the line between cure and comfort — and between hope and hopelessness — disrupting the fragile equilibrium that we doctors have long taken for granted.

(bluebird bio) Mar 28, 2018 - bluebird bio, Inc. and Celgene Corporation today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with...